(PDF) The FDA Black Box Warning Does Reduce the Use of

The FDA Black Box Warning Does Reduce the Use of Erythropoietin Stimulating Agents and Increases Blood Transfusions in Insured, Low Income Cancer Patients

Value in Health - United Kingdom

doi 10.1016/j.jval.2014.08.2392

Full Text

Open PDF

Abstract

Available in full text

Date

November 1, 2014

Authors

V. Noxon

C. Bennett

J. Wu

Publisher

Elsevier BV

Related search

FDA Urges "Black Box" Warning on Pediatric Antidepressants

CMAJ

Medicine

2004

English

The Suicide Epidemic in Youth and the FDA Black-Box Warning: Time to Reconsider

English

Impact of FDA Black Box Warning on Fluoroquinolone and Alternative Antibiotic Use in Southeastern US Hospitals

Infection Control and Hospital Epidemiology

English

Challenging the FDA Black Box Warning for High Aspirin Dose With Ticagrelor in Patients With Diabetes

English

Impacts of Black Box Warning, National Coverage Determination, and Risk Evaluation and Mitigation Strategies on the Inpatient On-Label and Off-Label Use of Erythropoiesis-Stimulating Agents

English

The Costs of Oral Versus Intravenous Chemotherapy in Insured, Low Income Patients With Breast or Colon Cancer

English

Trends in Utilization of Smoking Cessation Agents Before and After the Passage of Black Box Warning in the United States

English

A Retrospective Review of Blood Transfusions in Cancer Patients With Anemia

English

Red Blood Cell Transfusions in Very and Extremely Low Birthweight Infants Under Restrictive Transfusion Guidelines: Is Exogenous Erythropoietin Necessary?

Archives of Disease in Childhood: Fetal and Neonatal Edition

English

Amanote Research

The FDA Black Box Warning Does Reduce the Use of Erythropoietin Stimulating Agents and Increases Blood Transfusions in Insured, Low Income Cancer Patients

Value in Health - United Kingdom

doi 10.1016/j.jval.2014.08.2392

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

FDA Urges "Black Box" Warning on Pediatric Antidepressants

The Suicide Epidemic in Youth and the FDA Black-Box Warning: Time to Reconsider

Impact of FDA Black Box Warning on Fluoroquinolone and Alternative Antibiotic Use in Southeastern US Hospitals

Challenging the FDA Black Box Warning for High Aspirin Dose With Ticagrelor in Patients With Diabetes

Impacts of Black Box Warning, National Coverage Determination, and Risk Evaluation and Mitigation Strategies on the Inpatient On-Label and Off-Label Use of Erythropoiesis-Stimulating Agents

The Costs of Oral Versus Intravenous Chemotherapy in Insured, Low Income Patients With Breast or Colon Cancer

Trends in Utilization of Smoking Cessation Agents Before and After the Passage of Black Box Warning in the United States

A Retrospective Review of Blood Transfusions in Cancer Patients With Anemia

Red Blood Cell Transfusions in Very and Extremely Low Birthweight Infants Under Restrictive Transfusion Guidelines: Is Exogenous Erythropoietin Necessary?